Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Amarin Corporation is a biopharmaceutical company focused on the commercialization of its lead product, Vascepa, a prescription omega-3 fatty acid used to reduce cardiovascular risk. The company operates primarily in the United States, leveraging its unique clinical data that supports Vascepa's efficacy in reducing cardiovascular events, which differentiates it from competitors in the cardiovascular drug market.
Amarin generates revenue primarily through the sale of Vascepa, which is marketed directly to healthcare providers and patients. The company benefits from a strong clinical data backing, which supports pricing power and market penetration. Additionally, Amarin has established partnerships that contribute to its revenue stream.
Regulatory approvals for new indications of Vascepa
Sales growth of Vascepa in the U.S. market
Partnership developments or expansions
Clinical trial results for pipeline products
Regulatory changes affecting drug approvals and pricing
Technological advancements in cardiovascular treatments
Emergence of generic competitors for Vascepa
New entrants in the omega-3 market with innovative products
Limited cash reserves to fund ongoing R&D
Potential for increased operational losses if sales do not meet expectations
moderate - The demand for cardiovascular drugs can be influenced by overall healthcare spending, which is correlated with GDP growth.
Low - As a biopharmaceutical company, Amarin is less sensitive to interest rate changes; however, higher rates could impact consumer spending on healthcare.
minimal - The company has low debt levels, reducing its exposure to credit conditions.
growth - Investors looking for high-growth potential in the biopharmaceutical sector may be attracted to Amarin.
high - The stock has shown significant volatility, particularly around clinical trial results and regulatory news.
